Compare Repligen Corporation Common Stock (RGEN) vs TE Connectivity plc Ordinary Shares (TEL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TE Connectivity plc Ordinary Shares — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while TE Connectivity plc Ordinary Shares trades at $210.29 (market cap $62.51B). The key difference: TE Connectivity plc Ordinary Shares is far larger — about 5.6× Repligen Corporation Common Stock's market cap, and TE Connectivity plc Ordinary Shares pays a 1.44% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TE Connectivity plc Ordinary Shares for 0 Days on average.
| RGEN | TEL | |
|---|---|---|
Market Cap | $11.14B | $62.51B |
Volume | 1,259,263 | 2,249,319 |
Sector | Health | Technology |
52-Week High | $194.57 | $249.00 |
52-Week Low | $102.87 | $195.84 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $11.02B | $66.90B |
Dividend Yield | — | 1.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
TE Connectivity (TEL) trades at $215.92, down 0.63% with a bullish technical outlook. The stock shows strong fundamentals with consistent earnings beats, 15.61% net margin, and improving cash flow. Recent analyst upgrades highlight growth potential as the company prepares for Q4 2026 earnings on October 28.
TEL offers solid investment appeal with 23.54% ROE and 48% analyst buy ratings, though near-term volatility may persist. The $253.22 consensus target implies 17% upside, supported by operational strength and dividend stability. Key risks include market sensitivity and execution challenges in competitive electronics components sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TE Connectivity plc Ordinary Shares
TE Connectivity designs and manufactures connectivity and sensor solutions. Its products support transportation, energy networks, industrial automation, communications infrastructure, and medical technology.
Read more on TEL →
